128 related articles for article (PubMed ID: 17823384)
1. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Lee DH; Kim SW; Suh C; Lee JS; Lee JH; Lee SJ; Ryoo BY; Park K; Kim JS; Heo DS; Kim NK
Ann Oncol; 2008 Jan; 19(1):123-7. PubMed ID: 17823384
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
3. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Jeong J; Cho BC; Sohn JH; Choi HJ; Kim SH; Lee YJ; Jung MK; Shin SJ; Park MS; Kim SK; Chang J; Kim JH
Lung Cancer; 2010 Oct; 70(1):77-81. PubMed ID: 20138389
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Kim GM; Kim YS; Ae Kang Y; Jeong JH; Kim SM; Hong YK; Sung JH; Lim ST; Kim JH; Kim SK; Cho BC
J Thorac Oncol; 2012 Apr; 7(4):731-6. PubMed ID: 22425922
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Yeo CD; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim KH; Shim BY; Kim CH
Cancer Chemother Pharmacol; 2013 Oct; 72(4):809-14. PubMed ID: 23918044
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT
J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
15. Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.
Park YH; Chung CU; Park BM; Park MR; Park DI; Moon JY; Park HS; Kim JH; Jung SS; Kim JO; Kim SY; Lee JE
Can Respir J; 2016; 2016():3576201. PubMed ID: 28018128
[No Abstract] [Full Text] [Related]
16. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
[TBL] [Abstract][Full Text] [Related]
17. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
18. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
19. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
Masuda N; Fukuoka M; Kusunoki Y; Matsui K; Takifuji N; Kudoh S; Negoro S; Nishioka M; Nakagawa K; Takada M
J Clin Oncol; 1992 Aug; 10(8):1225-9. PubMed ID: 1321891
[TBL] [Abstract][Full Text] [Related]
20. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.
Choi HJ; Cho BC; Shin SJ; Cheon SH; Jung JY; Chang J; Kim SK; Sohn JH; Kim JH
Cancer Chemother Pharmacol; 2008 Feb; 61(2):309-13. PubMed ID: 17576560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]